Felipe Batalini, MD, Beth Israel Deaconess Medical Center, Boston, MA, expresses how the clinical benefit of poly(ADP-ribose) polymerase I (PARPi) in patients with metastatic breast cancer (mBC) is not limited to those women with inherited breast cancer susceptibility genes (BRCA1/2), but also to women with somatic BRCA mutations and other mutations in DNA repair genes. Progression-free survival (PFS) and overall survival (OS) were compared in mBC women with germline BRCA mutations and mBC women with somatic mutations in BRCA1/2 and other DNA repair genes given PARPi. PFS and OS were not significantly different in either group, demonstrating PARPi efficacy in mBC women with mutations other than germline BRCA1/2. These findings are consistent with the results of the TBCRC-048 trial. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
